Lilly halts two late-stage trials for Alzheimer's disease treatment

INDIANAPOLIS Lackluster results have prompted Eli Lilly to stop two late-stage clinical trials of a drug for treating Alzheimer’s disease, Lilly said Tuesday.

The drug maker said it would stop the phase-3 trials of semagacestat after preliminary results showed it did not slow the progression of the disease, while patients showed a worsening of cognitive functioning and the ability to perform daily activities.

Lilly said it still was investigating the monoclonal antibody solanezumab as a treatment for Alzheimer’s disease in another phase-3 trial.

Recommended stories

Login or Register to post a comment.